These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31759820)

  • 21. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caring for the Pediatric, Adolescent, or Young Adult Patient with Acute Lymphoblastic Leukemia.
    Balliot J; Morgan M; Cherven B
    Semin Oncol Nurs; 2019 Dec; 35(6):150956. PubMed ID: 31767263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nursing in pediatric oncology as shown for acute lymphatic leukemia].
    Bächle B; Niedoba D
    Pflege Aktuell; 1996 Jun; 50(6):434-40. PubMed ID: 8717020
    [No Abstract]   [Full Text] [Related]  

  • 25. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status of cancer immunotherapy for relapsed/refractory acute lymphoblastic leukemia in children and adolescents in Japan].
    Imai C
    Rinsho Ketsueki; 2020; 61(6):673-681. PubMed ID: 32624542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Relationship of Genetics, Nursing Practice, and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology [Formula: see text].
    Haylett WJ
    J Pediatr Oncol Nurs; 2017; 34(5):342-346. PubMed ID: 28681659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
    Hrabovský Š; Folber F; Doubek M
    Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Supporting Family Caregivers of Adult and Pediatric Persons with Leukemia.
    Dionne-Odom JN; Currie ER; Johnston EE; Rosenberg AR
    Semin Oncol Nurs; 2019 Dec; 35(6):150954. PubMed ID: 31753704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuing challenges and current issues in acute lymphoblastic leukemia.
    Kansagra A; Dahiya S; Litzow M
    Leuk Lymphoma; 2018 Mar; 59(3):526-541. PubMed ID: 28604239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR
    Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
    Maino E; Bonifacio M; Scattolin AM; Bassan R
    Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.